Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Blagden

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
BMC Developmental Biology|July 9, 2004
Hedgehog can drive terminal differentiation of amniote slow skeletal muscleXiaopeng Li, Christopher S Blagden, Heidi Bildsoe, et al.
Developmental Biology|July 18, 2001
Hedgehog signalling is required for maintenance of myf5 and myoD expression and timely terminal differentiation in zebrafish adaxial myogenesisO Coutelle, C S Blagden, R Hampson, et al.
British Journal of Cancer|September 17, 2002
Phase II study to evaluate combining gemcitabine with flutamide in advanced pancreatic cancer patientsP Corrie, A Mayer, J Shaw, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|August 19, 2014
Radiological predictors of cytoreductive outcomes in patients with advanced ovarian cancerJ Borley, C Wilhelm-Benartzi, J Yazbek, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 27, 2006
A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumoursA Greystoke, S Blagden, A L Thomas, et al.
European Journal of Cancer (Oxford, England : 1990)|April 10, 2019
Combining conventional therapy with immunotherapy: A risky business?A Coosemans, A Vankerckhoven, T Baert, et al.
British Journal of Cancer|August 11, 2012
Safety, cost-effectiveness and feasibility of daycase paracentesis in the management of malignant ascites with a focus on ovarian cancerV Harding, E Fenu, H Medani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 10, 2013
Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized studyC Fotopoulou, I Vergote, P Mainwaring, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
BMC Developmental Biology|July 9, 2004
Hedgehog can drive terminal differentiation of amniote slow skeletal muscleXiaopeng Li, Christopher S Blagden, Heidi Bildsoe, et al.
Developmental Biology|July 18, 2001
Hedgehog signalling is required for maintenance of myf5 and myoD expression and timely terminal differentiation in zebrafish adaxial myogenesisO Coutelle, C S Blagden, R Hampson, et al.
British Journal of Cancer|September 17, 2002
Phase II study to evaluate combining gemcitabine with flutamide in advanced pancreatic cancer patientsP Corrie, A Mayer, J Shaw, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|August 19, 2014
Radiological predictors of cytoreductive outcomes in patients with advanced ovarian cancerJ Borley, C Wilhelm-Benartzi, J Yazbek, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 27, 2006
A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumoursA Greystoke, S Blagden, A L Thomas, et al.
European Journal of Cancer (Oxford, England : 1990)|April 10, 2019
Combining conventional therapy with immunotherapy: A risky business?A Coosemans, A Vankerckhoven, T Baert, et al.
British Journal of Cancer|August 11, 2012
Safety, cost-effectiveness and feasibility of daycase paracentesis in the management of malignant ascites with a focus on ovarian cancerV Harding, E Fenu, H Medani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 10, 2013
Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized studyC Fotopoulou, I Vergote, P Mainwaring, et al.
Pageof 2